HPV 관련 암 치료 모니터링에서 액체 생검의 역할
액체 생검 - HPV 관련 질병의 치료 모니터링 및 조기 재발 감지를 위한 가능한 도구
This trial will evaluate the possible benefits and the performance of liquid biopsies in HPV-associated cancer treatment monitoring. This study aims to find a combination of an adequately sensitive and specific sampling method and biomarkers for early risk stratification of disease recurrence.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
상세 설명
Although the cancers associated with human papillomavirus (HPV) infection are currently almost entirely preventable, a significant part of the Czech population suffers from these diseases. The most common HPV-associated cancers are cervical cancer (CC) and oropharyngeal cancer (OPC). In these, the severe problem is successful monitoring of the treatment effectiveness and early disease recurrence detection. It is, therefore, necessary to find a non-invasive method that could specifically and timely identify patients at risk of recurrence and thus enable patients with quality and less burdensome medical care. The use of liquid biopsies (LB), which the study focuses on, looks most promising.
This study is divided into two arms, with each arm including both prospective and retrospective parts. Into prospective parts will be enrolled only newly diagnosed CC/HSIL (high-grade cervical intraepithelial lesions) or OPC patients. In contrast, the retrospective part will enroll patients in post-treatment follow-up. In both study arms, fresh tumor tissues will be sampled from patients in prospective parts before treatment, and archived Formalin Fixed Paraffin Embedded (FFPE) tissue samples will be obtained from patients of retrospective parts.
Regarding the liquid biopsies, pre & post-treatment sampling of LB will be performed. Subsequently, regular sample acquisition will be performed during follow-up according to the standard medical practice in both prospective and retrospective parts. Oropharyngeal swabs, gargle lavage,exhaled breath condensate (EBC), and blood samples will be collected from OPC patients. Blood collection and self-sampling of cervicovaginal swabs will be performed in patients with CC/HSIL. All samples, excluding blood samples, will be tested for the presence of the most prevalent high-risk and low-risk HPV genotypes. The circulating tumor (ct) HPV DNA will be monitored in blood samples. Additionally, the mutation profile of the primary tumors will be examined in fresh and FFPE samples.
The dynamics of HPV DNA will be monitored throughout all follow-up samples and correlated with the obtained clinical data. A created panel of frequently altered genes will be used for alterations monitoring in liquid biopsies. In the final analysis of laboratory and clinical results, we assume a finding of a clinically usable algorithm that could predict the risk of disease recurrence for a particular patient.
연구 유형
연구 유형
등록 (추정된)
등록
연락처 및 위치
연구 연락처
연구 연락처
- 이름: Vladimira Koudelakova, MSc, Ph.D.
- 전화번호: +420 585 632 089
- 이메일: vladimira.koudelakova@upol.cz
연구 연락처 백업
- 이름: Marian Hajduch, MD., PhD.
- 전화번호: +420 585 632 083
- 이메일: marian.hajduch@upol.cz
연구 장소
-
-
-
Olomouc, 체코, 77900
- 모병
- University Hospital Olomouc
-
연락하다:
- Marian Hajduch, MD, PhD.
- 전화번호: +420 585 632 083
- 이메일: marian.hajduch@upol.cz
-
연락하다:
- Vladimira Koudelakova, MSc., PhD.
- 전화번호: +420 585 632 089
- 이메일: vladimira.koudelakova@upol.cz
-
수석 연구원:
- Radovan Pilka, prof. MD,PhD
-
수석 연구원:
- Richard Salzman, MD, PhD.
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
샘플링 방법
연구 인구
Oropharyngeal cancer patients, Cervical cancer patients
설명
Inclusion Criteria:
Women diagnosed with CC/HSIL. Men and women diagnosed with OPC. Patients must agree with study enrollment and must sign study informed consent.
Exclusion Criteria:
No exclusion criteria are set.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 관찰 모델: COHORT
- 시간 관점: OTHER
그룹/코호트 수
코호트 및 개입
그룹/코호트그룹/코호트 |
개입 / 치료개입 / 치료 |
|---|---|
|
Arm A - Oropharyngeal cancer patients
In total, approx. 200 OPC cancer patients will be enrolled in the study Arm A, with both prospective and retrospective parts enrolling 100 OPC patients. The Arm A will enroll patients from the Department of Otorhinolaryngology and Head and Neck Surgery, University Hospital Olomouc. Pre-treatment primary samples of fresh or FFPE tissue samples will be collected. Liquid biopsies (gargle lavage, oropharyngeal smear, breath condensate, and blood sample) will be collected. Obtained samples will be tested by CE-IVD (device complies with European in vitro diagnostic Directive) marked HPV diagnostic test. A laboratory developed digital droplet PCR assay will be used for ct HPV DNA detection. Sampling will be performed at pre & post treatment check-ups, and every 3 months for 3 years and every 6 months for 2 years. |
Patients will be asked to perform self-collection of gargle lavage samples. Oropharyngeal swabs, breath condensate, and blood samples will be taken by trained clinicians. |
|
Arm B - Cervical cancer patients
Into the study Arm B will be enrolled 80 patients with CC and 120 patients with HSIL, and 80 patients will be enrolled into the retrospective part. The Arm B will enroll patients from the Department of Gynecology and Obstetrics, University Hospital Olomouc. Pre-treatment primary samples of fresh or FFPE tissue samples will be collected. Liquid biopsies (cervicovaginal swab and blood sample) will be collected. Obtained samples will be tested by CE-IVD marked HPV diagnostic test. A laboratory developed digital droplet PCR assay will be used for ct HPV DNA detection. Sampling will be performed at pre & post treatment check-ups, and every 3 months for 2 years and every 6 months for 3 years. |
Patients will be asked to perform cervicovaginal self-sampling using Evalyn Brush. Blood samples will be taken by trained clinicians. |
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Dynamics of HPV infection in cervical cancer patients during 4-year follow-up.
기간: 4 years
|
HPV-status in liquid biopsies collected during pre-treatment, post-treatment and follow-up check-ups. |
4 years
|
|
Dynamics of HPV infection in oropharyngeal cancer patients during 4-year follow-up.
기간: 4 years
|
HPV-status in liquid biopsies collected during pre-treatment, post-treatment and follow-up check-ups. |
4 years
|
|
Dynamics of circulating tumor (ct) HPV DNA in oropharyngeal cancer patients.
기간: 4 years
|
Correlation of plasmatic ct HPV DNA level with cancer patient´s prognosis. |
4 years
|
|
Dynamics of circulating tumor (ct) HPV DNA in cervical cancer patients
기간: 4 years
|
Correlation of plasmatic ct HPV DNA level with patient´s prognosis |
4 years
|
|
Analysis of the mutational landscape of oropharyngeal cancer cases.
기간: 4 years
|
Correlation of tumor mutational burden (TMB) with cancer patient´s prognosis. |
4 years
|
|
Analysis of the mutational landscape of cervical cancer cases.
기간: 4 years
|
Correlation of tumor mutational burden (TMB) with cancer patient´s prognosis. |
4 years
|
공동 작업자 및 조사자
스폰서
스폰서
협력자
협력자
수사관
수사관
- 연구 책임자: Marian Hajduch, MD., PhD., IMTM, Palacky University in Olomouc, Faculty of Medicine and Dentistry
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
- 비뇨생식기 질환
- 생식기 질환
- 악구강 질환
- 병리학적 과정
- 비뇨생식기 신생물
- 부위별 신생물
- 신생물
- 여성 비뇨 생식기 질환
- 여성 비뇨 생식기 질환 및 임신 합병증
- 질병 속성
- 감염
- 바이러스 질환
- 자궁 질환
- 생식기 질환, 여성
- 두경부 신생물
- 전염병
- 성병, 바이러스성
- 성병
- DNA 바이러스 감염
- 생식기 신생물, 여성
- 전암 상태
- 자궁 경부 질환
- 이비인후과 질환
- 자궁 신생물
- 인두 신생물
- 이비인후과 신생물
- 인두 질환
- 종양 바이러스 감염
- 병리학적 상태, 징후 및 증상
- 자궁경부 신생물
- 유두종 바이러스 감염
- 자궁 경부 이형성증
- 구인두 신생물
- 조사 기술
- 시편 처리
- 임상 실험실 기술
- 진단 기술 및 절차
- 진단
- 세포 학적 기술
- 생검
- 세포 진단
- 액체 생검
기타 연구 ID 번호
기타 연구 ID 번호
- NU-23-03-00255
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .